| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 39 | 2020 | 471 | 8.210 |
Why?
|
| Exosomes | 10 | 2020 | 43 | 5.600 |
Why?
|
| Silymarin | 32 | 2016 | 36 | 5.520 |
Why?
|
| Antineoplastic Agents | 15 | 2020 | 608 | 2.390 |
Why?
|
| Signal Transduction | 20 | 2019 | 682 | 2.330 |
Why?
|
| Cell Line, Tumor | 38 | 2019 | 726 | 2.320 |
Why?
|
| Cell Proliferation | 22 | 2020 | 604 | 1.850 |
Why?
|
| Neoplasms | 7 | 2020 | 726 | 1.750 |
Why?
|
| Antineoplastic Agents, Phytogenic | 9 | 2019 | 37 | 1.740 |
Why?
|
| Apoptosis | 19 | 2015 | 360 | 1.680 |
Why?
|
| Antioxidants | 16 | 2016 | 115 | 1.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 261 | 1.420 |
Why?
|
| Qa-SNARE Proteins | 2 | 2019 | 6 | 1.360 |
Why?
|
| Cell Hypoxia | 7 | 2020 | 41 | 1.250 |
Why?
|
| Animals | 47 | 2020 | 7541 | 1.210 |
Why?
|
| Plant Extracts | 6 | 2016 | 61 | 1.200 |
Why?
|
| Humans | 70 | 2020 | 32005 | 1.090 |
Why?
|
| Male | 52 | 2020 | 19165 | 1.080 |
Why?
|
| Cell Survival | 13 | 2020 | 284 | 1.040 |
Why?
|
| Cell Movement | 7 | 2019 | 169 | 1.030 |
Why?
|
| Oxidative Stress | 5 | 2017 | 231 | 0.960 |
Why?
|
| Mice | 31 | 2019 | 2484 | 0.940 |
Why?
|
| Prostate | 7 | 2020 | 68 | 0.940 |
Why?
|
| African Americans | 4 | 2019 | 1425 | 0.920 |
Why?
|
| Cadherins | 4 | 2016 | 26 | 0.910 |
Why?
|
| Mice, Nude | 16 | 2020 | 291 | 0.910 |
Why?
|
| Pentacyclic Triterpenes | 2 | 2014 | 2 | 0.880 |
Why?
|
| Anticarcinogenic Agents | 8 | 2014 | 25 | 0.860 |
Why?
|
| Neovascularization, Pathologic | 5 | 2016 | 82 | 0.860 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 190 | 0.850 |
Why?
|
| Skin Neoplasms | 7 | 2019 | 214 | 0.840 |
Why?
|
| Milk Thistle | 7 | 2016 | 7 | 0.830 |
Why?
|
| Cell Cycle Proteins | 6 | 2015 | 55 | 0.760 |
Why?
|
| Cell Cycle | 5 | 2015 | 77 | 0.750 |
Why?
|
| Proteome | 2 | 2019 | 39 | 0.750 |
Why?
|
| Phenylthiohydantoin | 2 | 2019 | 7 | 0.740 |
Why?
|
| Matrix Metalloproteinases | 1 | 2020 | 11 | 0.700 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 41 | 0.700 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2016 | 115 | 0.700 |
Why?
|
| NF-kappa B | 6 | 2016 | 81 | 0.660 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 220 | 0.640 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2019 | 104 | 0.620 |
Why?
|
| Proteomics | 1 | 2019 | 94 | 0.620 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 23 | 0.610 |
Why?
|
| Integrins | 2 | 2015 | 41 | 0.600 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 114 | 0.590 |
Why?
|
| Disease Progression | 5 | 2017 | 594 | 0.590 |
Why?
|
| Placenta | 1 | 2018 | 74 | 0.580 |
Why?
|
| Lipid Metabolism | 3 | 2016 | 105 | 0.580 |
Why?
|
| Adenocarcinoma | 4 | 2016 | 308 | 0.580 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2016 | 23 | 0.570 |
Why?
|
| Phenotype | 1 | 2019 | 632 | 0.570 |
Why?
|
| Organoids | 1 | 2018 | 94 | 0.560 |
Why?
|
| Ultraviolet Rays | 5 | 2019 | 51 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2018 | 70 | 0.560 |
Why?
|
| Neoplasm Proteins | 4 | 2014 | 148 | 0.560 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2019 | 26 | 0.550 |
Why?
|
| Lipogenesis | 1 | 2016 | 18 | 0.550 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2016 | 10 | 0.540 |
Why?
|
| Metabolomics | 1 | 2016 | 54 | 0.540 |
Why?
|
| Transcription Factors | 2 | 2014 | 181 | 0.540 |
Why?
|
| Biomedical Research | 1 | 2018 | 156 | 0.540 |
Why?
|
| DNA Damage | 6 | 2019 | 98 | 0.530 |
Why?
|
| Prognosis | 6 | 2020 | 1497 | 0.530 |
Why?
|
| Momordica charantia | 3 | 2018 | 3 | 0.520 |
Why?
|
| Stem Cells | 1 | 2018 | 313 | 0.510 |
Why?
|
| Flavonolignans | 2 | 2012 | 2 | 0.490 |
Why?
|
| Fibronectins | 1 | 2014 | 36 | 0.480 |
Why?
|
| Oxygen | 1 | 2015 | 142 | 0.480 |
Why?
|
| Triglycerides | 1 | 2015 | 230 | 0.480 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2011 | 36 | 0.470 |
Why?
|
| Adherens Junctions | 1 | 2013 | 1 | 0.470 |
Why?
|
| Endothelial Cells | 2 | 2015 | 189 | 0.460 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 104 | 0.450 |
Why?
|
| Carcinoma | 3 | 2011 | 91 | 0.440 |
Why?
|
| Carcinogens | 4 | 2013 | 35 | 0.440 |
Why?
|
| Glioblastoma | 1 | 2014 | 156 | 0.420 |
Why?
|
| Blotting, Western | 7 | 2014 | 289 | 0.410 |
Why?
|
| Biological Products | 2 | 2015 | 77 | 0.400 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2016 | 82 | 0.360 |
Why?
|
| Enzyme Activation | 6 | 2020 | 135 | 0.360 |
Why?
|
| Receptors, Androgen | 1 | 2010 | 47 | 0.350 |
Why?
|
| Glioma | 1 | 2011 | 136 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 3 | 2018 | 134 | 0.350 |
Why?
|
| Kava | 1 | 2008 | 1 | 0.330 |
Why?
|
| Protective Agents | 1 | 2008 | 4 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2018 | 37 | 0.320 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 638 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2014 | 154 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2008 | 458 | 0.300 |
Why?
|
| Mice, Transgenic | 6 | 2019 | 264 | 0.300 |
Why?
|
| Pyrones | 2 | 2018 | 4 | 0.290 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 538 | 0.290 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2017 | 37 | 0.290 |
Why?
|
| Head and Neck Neoplasms | 3 | 2014 | 130 | 0.290 |
Why?
|
| Anthocyanins | 2 | 2017 | 3 | 0.280 |
Why?
|
| Autophagy | 2 | 2018 | 52 | 0.280 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2020 | 58 | 0.270 |
Why?
|
| Fibroblasts | 3 | 2016 | 111 | 0.270 |
Why?
|
| DNA Repair | 4 | 2015 | 64 | 0.260 |
Why?
|
| European Continental Ancestry Group | 3 | 2019 | 1166 | 0.260 |
Why?
|
| Neurons | 2 | 2019 | 410 | 0.240 |
Why?
|
| Microscopy, Confocal | 3 | 2015 | 65 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2011 | 112 | 0.240 |
Why?
|
| Grape Seed Extract | 2 | 2014 | 2 | 0.240 |
Why?
|
| Macrophages | 2 | 2019 | 191 | 0.240 |
Why?
|
| Benzo(a)pyrene | 1 | 2004 | 2 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2017 | 36 | 0.230 |
Why?
|
| Cyclin-Dependent Kinases | 3 | 2008 | 9 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2017 | 43 | 0.230 |
Why?
|
| Chemoprevention | 4 | 2019 | 11 | 0.220 |
Why?
|
| Stomach Neoplasms | 1 | 2004 | 84 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 2 | 2015 | 61 | 0.220 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2011 | 14 | 0.220 |
Why?
|
| Carnitine O-Palmitoyltransferase | 2 | 2019 | 8 | 0.210 |
Why?
|
| Lung Neoplasms | 4 | 2011 | 412 | 0.200 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 1022 | 0.200 |
Why?
|
| Transcription Factor AP-1 | 4 | 2016 | 19 | 0.190 |
Why?
|
| Osmium | 1 | 2020 | 1 | 0.190 |
Why?
|
| Coordination Complexes | 1 | 2020 | 9 | 0.190 |
Why?
|
| Cell Separation | 2 | 2018 | 92 | 0.180 |
Why?
|
| Thiophenes | 1 | 2020 | 23 | 0.180 |
Why?
|
| Photosensitizing Agents | 1 | 2020 | 24 | 0.180 |
Why?
|
| Photochemotherapy | 1 | 2020 | 21 | 0.180 |
Why?
|
| Hedgehog Proteins | 2 | 2017 | 9 | 0.180 |
Why?
|
| Skin | 4 | 2019 | 211 | 0.170 |
Why?
|
| Androgens | 1 | 2019 | 30 | 0.170 |
Why?
|
| Androgen Antagonists | 1 | 2019 | 19 | 0.170 |
Why?
|
| Mast Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2019 | 20 | 0.170 |
Why?
|
| Obesity | 2 | 2018 | 1175 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 447 | 0.170 |
Why?
|
| Cytoplasm | 1 | 2019 | 29 | 0.170 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 43 | 0.160 |
Why?
|
| Gene Silencing | 1 | 2019 | 48 | 0.160 |
Why?
|
| Receptors, Notch | 1 | 2018 | 16 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 7 | 2018 | 767 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 40 | 0.160 |
Why?
|
| United States | 2 | 2018 | 3939 | 0.160 |
Why?
|
| Molecular Imaging | 1 | 2019 | 20 | 0.160 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 60 | 0.160 |
Why?
|
| Serotonin | 1 | 2018 | 37 | 0.160 |
Why?
|
| Ascomycota | 1 | 2018 | 4 | 0.160 |
Why?
|
| Neural Cell Adhesion Molecule L1 | 1 | 2018 | 2 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 317 | 0.160 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2018 | 3 | 0.160 |
Why?
|
| Benzylidene Compounds | 1 | 2018 | 7 | 0.160 |
Why?
|
| Aniline Compounds | 1 | 2018 | 18 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 104 | 0.150 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 12 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 45 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 2 | 2008 | 3 | 0.150 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2017 | 5 | 0.150 |
Why?
|
| Biopsy | 1 | 2019 | 259 | 0.150 |
Why?
|
| Cell Line | 3 | 2015 | 435 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 99 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2019 | 180 | 0.140 |
Why?
|
| Mitochondria | 2 | 2017 | 187 | 0.140 |
Why?
|
| Transfection | 2 | 2014 | 191 | 0.140 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 173 | 0.140 |
Why?
|
| Calcium | 1 | 2019 | 307 | 0.140 |
Why?
|
| Lipids | 1 | 2018 | 232 | 0.140 |
Why?
|
| Stilbenes | 2 | 2013 | 23 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 167 | 0.140 |
Why?
|
| Talaromyces | 1 | 2016 | 1 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 114 | 0.140 |
Why?
|
| Annonaceae | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 57 | 0.140 |
Why?
|
| Terpenes | 1 | 2016 | 7 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 18 | 0.130 |
Why?
|
| Female | 7 | 2019 | 19959 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 48 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 15 | 0.130 |
Why?
|
| Naphthols | 1 | 2015 | 1 | 0.130 |
Why?
|
| Culture Media, Conditioned | 2 | 2016 | 51 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 301 | 0.130 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 24 | 0.130 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 101 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2014 | 833 | 0.130 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 157 | 0.130 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 75 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 582 | 0.130 |
Why?
|
| Naphthalenes | 1 | 2015 | 40 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 876 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 50 | 0.130 |
Why?
|
| Electron Transport Complex III | 1 | 2014 | 1 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 23 | 0.120 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 633 | 0.120 |
Why?
|
| Time Factors | 3 | 2008 | 2149 | 0.120 |
Why?
|
| Pregnancy | 1 | 2018 | 997 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 2014 | 55 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 153 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2016 | 3306 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2014 | 58 | 0.120 |
Why?
|
| Dacarbazine | 1 | 2014 | 29 | 0.120 |
Why?
|
| STAT1 Transcription Factor | 2 | 2011 | 12 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 170 | 0.120 |
Why?
|
| Inflammation | 2 | 2016 | 530 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 2 | 2011 | 25 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2014 | 26 | 0.120 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Glucose | 1 | 2015 | 174 | 0.120 |
Why?
|
| Metalloproteases | 1 | 2013 | 4 | 0.120 |
Why?
|
| Annexin A2 | 1 | 2013 | 7 | 0.120 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2013 | 1 | 0.120 |
Why?
|
| Tongue Neoplasms | 1 | 2013 | 5 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 77 | 0.110 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 34 | 0.110 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 33 | 0.110 |
Why?
|
| Coculture Techniques | 1 | 2013 | 81 | 0.110 |
Why?
|
| Momordica | 1 | 2013 | 1 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2013 | 26 | 0.110 |
Why?
|
| Interleukin-12 | 1 | 2013 | 28 | 0.110 |
Why?
|
| RANK Ligand | 1 | 2012 | 4 | 0.110 |
Why?
|
| NFATC Transcription Factors | 1 | 2012 | 5 | 0.110 |
Why?
|
| Osteoclasts | 1 | 2012 | 22 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 245 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 411 | 0.100 |
Why?
|
| Metformin | 1 | 2012 | 22 | 0.100 |
Why?
|
| Seeds | 1 | 2012 | 10 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 40 | 0.100 |
Why?
|
| Vitis | 1 | 2012 | 12 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 166 | 0.100 |
Why?
|
| Transplantation, Heterologous | 2 | 2008 | 122 | 0.100 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2008 | 31 | 0.100 |
Why?
|
| Microcirculation | 2 | 2008 | 65 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2011 | 16 | 0.100 |
Why?
|
| Cytokines | 2 | 2012 | 256 | 0.090 |
Why?
|
| Cell Death | 3 | 2017 | 77 | 0.090 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 6 | 0.090 |
Why?
|
| Brain | 1 | 2018 | 951 | 0.090 |
Why?
|
| Caspase 8 | 1 | 2010 | 10 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2010 | 22 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2007 | 4 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2007 | 35 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 495 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 71 | 0.090 |
Why?
|
| Wound Healing | 1 | 2011 | 185 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2010 | 108 | 0.090 |
Why?
|
| Cyclin D1 | 3 | 2019 | 14 | 0.080 |
Why?
|
| Beverages | 1 | 2008 | 19 | 0.080 |
Why?
|
| cdc25 Phosphatases | 1 | 2008 | 1 | 0.080 |
Why?
|
| Isomerism | 1 | 2008 | 7 | 0.080 |
Why?
|
| Cyclins | 1 | 2008 | 6 | 0.080 |
Why?
|
| Aged | 2 | 2019 | 10301 | 0.080 |
Why?
|
| Antimitotic Agents | 1 | 2008 | 2 | 0.080 |
Why?
|
| Gallic Acid | 1 | 2008 | 2 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2014 | 229 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 80 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2008 | 185 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2008 | 142 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1128 | 0.080 |
Why?
|
| Middle Aged | 2 | 2019 | 11817 | 0.070 |
Why?
|
| Mitosis | 1 | 2007 | 25 | 0.070 |
Why?
|
| Light | 1 | 2007 | 24 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2007 | 22 | 0.070 |
Why?
|
| Caspases | 1 | 2007 | 39 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 215 | 0.070 |
Why?
|
| Immunoblotting | 2 | 2017 | 51 | 0.070 |
Why?
|
| Neoplasm Transplantation | 3 | 2014 | 73 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 99 | 0.070 |
Why?
|
| Body Weight | 2 | 2008 | 310 | 0.070 |
Why?
|
| Gene Expression | 2 | 2018 | 338 | 0.060 |
Why?
|
| Models, Biological | 1 | 2007 | 392 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2016 | 59 | 0.060 |
Why?
|
| Mice, Hairless | 2 | 2016 | 2 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2016 | 443 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 268 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 29 | 0.060 |
Why?
|
| Cell Division | 2 | 2015 | 99 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2013 | 33 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 52 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2014 | 469 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2012 | 9 | 0.040 |
Why?
|
| Acetylation | 1 | 2019 | 15 | 0.040 |
Why?
|
| Histone Acetyltransferases | 1 | 2019 | 7 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 53 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 78 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2018 | 1 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 26 | 0.040 |
Why?
|
| Fresh Water | 1 | 2018 | 3 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 71 | 0.040 |
Why?
|
| Sepharose | 1 | 2018 | 6 | 0.040 |
Why?
|
| Biotinylation | 1 | 2018 | 10 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2018 | 160 | 0.040 |
Why?
|
| Protein Binding | 1 | 2018 | 201 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 90 | 0.040 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2016 | 2 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 13 | 0.030 |
Why?
|
| Plant Leaves | 1 | 2016 | 6 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2016 | 20 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 90 | 0.030 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2015 | 2 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2015 | 4 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2016 | 80 | 0.030 |
Why?
|
| Dermis | 1 | 2015 | 16 | 0.030 |
Why?
|
| Penicillium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Diketopiperazines | 1 | 2015 | 1 | 0.030 |
Why?
|
| Lactones | 1 | 2015 | 10 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 23 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 103 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2015 | 7 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 56 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 263 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2014 | 6 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 12 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 147 | 0.030 |
Why?
|
| Metribolone | 1 | 2014 | 2 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Mitochondrial Membranes | 1 | 2014 | 21 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 27 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2015 | 68 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2016 | 147 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 923 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1188 | 0.030 |
Why?
|
| Pyridines | 1 | 2014 | 76 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2014 | 10 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 163 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 154 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 12 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 181 | 0.030 |
Why?
|
| Tongue | 1 | 2013 | 13 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2013 | 11 | 0.030 |
Why?
|
| Cytosol | 1 | 2013 | 25 | 0.030 |
Why?
|
| Radiation-Protective Agents | 1 | 2013 | 5 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 80 | 0.030 |
Why?
|
| Epidermis | 1 | 2013 | 30 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2012 | 18 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 167 | 0.030 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Cyclin E | 1 | 2012 | 5 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2012 | 2 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 10 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 22 | 0.030 |
Why?
|
| G2 Phase | 1 | 2012 | 17 | 0.030 |
Why?
|
| Pyrimidine Dimers | 1 | 2011 | 1 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2011 | 5 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 91 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 76 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 105 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 9 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Species Specificity | 1 | 2007 | 90 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 34 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2008 | 187 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 35 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 155 | 0.020 |
Why?
|
| Urethane | 1 | 2006 | 1 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 17 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 48 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 201 | 0.020 |
Why?
|
| Adult | 1 | 2018 | 9345 | 0.020 |
Why?
|
| Diet | 1 | 2007 | 391 | 0.020 |
Why?
|